Zoetis Inc (ZTS)

Zoetis Inc. is a U.S.-listed common equity security representing the animal health company Zoetis Inc., which is traded on the NYSE under the symbol ZTS. The company develops, manufactures, and commercializes a broad range of animal health products and related solutions, including medicines, vaccines, diagnostics, biodevices, genetic tests, and precision animal health tools. Its business serves both companion animals such as dogs, cats, and horses, and livestock species including cattle, swine, poultry, fish, and sheep. Zoetis also sells parasiticides, dermatology products, anti-infectives, pain and sedation treatments, nutritionals, and diagnostic products and services. Its customer base includes veterinarians, livestock producers, and pet owners. Founded in 2012, the company is headquartered in Parsippany, New Jersey, and has also worked with Blacksmith Medicines, Inc. on antibiotic discovery for animal health.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-ZTS
$124.22
64.6% Upside
Bargain
$114.76
52.0% Upside
Bargain
Great
July 20, 2026
September 1, 2026
2.12
2.8%
August 6, 2026
11.8x
9.7x
3.3x
31.945 B
38.831 B
22.5%
99.8%
5.7
33.3%
83.7%
Valuation • Fair Value

Zoetis Inc (NYSE-ZTS) Fair Value by Valuation Model

Compare the primary fair value estimate for Zoetis Inc (NYSE-ZTS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$124.22

Estimated upside of 64.6% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$139.61

Discounted cash flow valuation reference.

Ben Graham Formula Value

$70.72

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$81.94

Earnings power value estimate.

Comps Fair Value

$115.89

Comparable-company valuation reference.

Analyst Price Target

$114.76

Analysts imply upside of 52.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Zoetis Inc (NYSE-ZTS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Zoetis Inc (NYSE-ZTS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

9.531 B

Current operating scale indicator.

Revenue Forecast

9.723 B

Forward revenue estimate.

EBITDA

4.074 B

Current operating profitability reference.

EBITDA Forecast

4.292 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Zoetis Inc (NYSE-ZTS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Zoetis Inc (NYSE-ZTS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.45

No elevated caution signal from this screen.

Altman Z-Score

5.7

Relatively strong balance-sheet zone.

FCF / Net Income

83.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Zoetis Inc (NYSE-ZTS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Zoetis Inc (NYSE-ZTS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

September 1, 2026

Ex-Dividend Date

July 20, 2026

Dividend Yield

2.8%

Income yield reference.

Upcoming Dividend

2.12

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

33.3%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Zoetis Inc (NYSE-ZTS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Zoetis Inc (NYSE-ZTS) Stock Forecast & Technical Outlook

Review Zoetis Inc (NYSE-ZTS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Zoetis Inc (NYSE-ZTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Zoetis Inc (NYSE-ZTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Zoetis Inc (NYSE-ZTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Zoetis Inc (NYSE-ZTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Zoetis Inc (NYSE-ZTS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Zoetis Inc (NYSE-ZTS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Zoetis Inc (NYSE-ZTS) has a Hold consensus, with 8 buy, 9 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 9
Sell 0
FAQ Fast Investor Answers

Zoetis Inc (NYSE-ZTS) Stock FAQ

Quick answers about Zoetis Inc (NYSE-ZTS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$124.22
Estimated upside 64.6%
Valuation Rating
Undervalued
Estimated upside of 64.6%
Analyst Target
$114.76
Implied upside 52.0%
Financial Health
Great
Current financial-health read

The current fair value estimate for Zoetis Inc (NYSE-ZTS) is $124.22. This implies an estimated upside of 64.6% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 64.6% versus the current market price.

The available analyst price target for Zoetis Inc (NYSE-ZTS) is $114.76. The analyst target implies estimated upside of 52.0%.

The current financial health read for Zoetis Inc (NYSE-ZTS) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Zoetis Inc (NYSE-ZTS) is August 6, 2026.

Based on the current data, dividend yield is 2.8%, upcoming dividend amount is 2.12, ex-dividend date is July 20, 2026, payment date is September 1, 2026.

The current P/E ratio listed for Zoetis Inc (NYSE-ZTS) is 11.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Zoetis Inc is 31.945 B.

The current enterprise value listed for Zoetis Inc is 38.831 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Zoetis Inc is NYSE-ZTS, and the stock is listed on NYSE.

Zoetis Inc (NYSE-ZTS) is listed on NYSE.

The current debt-to-total-capital ratio listed for Zoetis Inc is 22.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Zoetis Inc is 99.8%. Free float helps investors understand how much of the share base is available for public trading.